Key clinical point: First-line lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) is a well-tolerated and effective treatment for patients with high-risk advanced hepatocellular carcinoma (HCC).
Major finding: The progression-free survival (PFS) of 80.6% (95% CI 64.0%-91.8%) of patients was >6 months, and the median PFS was 10.4 months (95% CI 5.8-15.0 months). The median overall survival was not reached at the prespecified final analysis. The objective response rate was 63.9%. Serious treatment-related adverse events occurred in 38.9% of patients.
Study details: This single-center, phase 2 trial included 36 adult treatment-naive patients with advanced HCC (86.1% with high-risk features) who received lenvatinib, toripalimab, and FOLFOX-HAIC.
Disclosures: This study was supported by the National Natural Science Foundation of China, Development Planned Project in Key Areas of Guangdong Province, and the China Postdoctoral Science Foundation. The authors declared no conflicts of interest.
Source: Lai ZC, He MK, Bu XY, Xu YJ, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial. Eur J Cancer. 2022;174:68-77 (Aug 15). Doi: 10.1016/j.ejca.2022.07.005
